S&P 500   4,291.00 (-0.20%)
DOW   33,516.77 (-0.44%)
QQQ   358.28 (+0.08%)
AAPL   171.14 (+0.26%)
MSFT   316.02 (+0.76%)
META   300.30 (-1.20%)
GOOGL   130.83 (-1.12%)
AMZN   127.28 (+1.03%)
TSLA   249.68 (+1.34%)
NVDA   435.27 (+1.02%)
NIO   8.99 (+0.90%)
BABA   86.76 (+1.43%)
AMD   103.30 (+0.53%)
T   15.01 (+0.00%)
F   12.41 (-1.19%)
MU   68.20 (+4.60%)
CGC   0.79 (-2.90%)
GE   110.45 (-1.68%)
DIS   80.93 (+1.00%)
AMC   7.93 (+1.80%)
PFE   33.12 (+3.21%)
PYPL   58.31 (+0.22%)
NFLX   376.41 (+0.01%)
S&P 500   4,291.00 (-0.20%)
DOW   33,516.77 (-0.44%)
QQQ   358.28 (+0.08%)
AAPL   171.14 (+0.26%)
MSFT   316.02 (+0.76%)
META   300.30 (-1.20%)
GOOGL   130.83 (-1.12%)
AMZN   127.28 (+1.03%)
TSLA   249.68 (+1.34%)
NVDA   435.27 (+1.02%)
NIO   8.99 (+0.90%)
BABA   86.76 (+1.43%)
AMD   103.30 (+0.53%)
T   15.01 (+0.00%)
F   12.41 (-1.19%)
MU   68.20 (+4.60%)
CGC   0.79 (-2.90%)
GE   110.45 (-1.68%)
DIS   80.93 (+1.00%)
AMC   7.93 (+1.80%)
PFE   33.12 (+3.21%)
PYPL   58.31 (+0.22%)
NFLX   376.41 (+0.01%)
S&P 500   4,291.00 (-0.20%)
DOW   33,516.77 (-0.44%)
QQQ   358.28 (+0.08%)
AAPL   171.14 (+0.26%)
MSFT   316.02 (+0.76%)
META   300.30 (-1.20%)
GOOGL   130.83 (-1.12%)
AMZN   127.28 (+1.03%)
TSLA   249.68 (+1.34%)
NVDA   435.27 (+1.02%)
NIO   8.99 (+0.90%)
BABA   86.76 (+1.43%)
AMD   103.30 (+0.53%)
T   15.01 (+0.00%)
F   12.41 (-1.19%)
MU   68.20 (+4.60%)
CGC   0.79 (-2.90%)
GE   110.45 (-1.68%)
DIS   80.93 (+1.00%)
AMC   7.93 (+1.80%)
PFE   33.12 (+3.21%)
PYPL   58.31 (+0.22%)
NFLX   376.41 (+0.01%)
S&P 500   4,291.00 (-0.20%)
DOW   33,516.77 (-0.44%)
QQQ   358.28 (+0.08%)
AAPL   171.14 (+0.26%)
MSFT   316.02 (+0.76%)
META   300.30 (-1.20%)
GOOGL   130.83 (-1.12%)
AMZN   127.28 (+1.03%)
TSLA   249.68 (+1.34%)
NVDA   435.27 (+1.02%)
NIO   8.99 (+0.90%)
BABA   86.76 (+1.43%)
AMD   103.30 (+0.53%)
T   15.01 (+0.00%)
F   12.41 (-1.19%)
MU   68.20 (+4.60%)
CGC   0.79 (-2.90%)
GE   110.45 (-1.68%)
DIS   80.93 (+1.00%)
AMC   7.93 (+1.80%)
PFE   33.12 (+3.21%)
PYPL   58.31 (+0.22%)
NFLX   376.41 (+0.01%)
LON:CLIN

Clinigen Group (CLIN) Share Forecast, Price & News

GBX 925
0.00 (0.00%)
(As of 04/4/2022)
Compare
Today's Range
925
925
50-Day Range
925
925
52-Week Range
541.50
948.05
Volume
539,375 shs
Average Volume
1.83 million shs
Market Capitalization
£1.23 billion
P/E Ratio
64.69
Dividend Yield
0.01%
Price Target
N/A

CLIN stock logo

About Clinigen Group (LON:CLIN) Stock

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

CLIN Price History

CLIN Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
EQS-News: PAION AG reports on fiscal year 2022
Amifostine Market Growth and Forecast till 2031
See More Headlines
Receive CLIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter.

CLIN Company Calendar

Last Earnings
9/17/2020
Today
9/29/2023

Industry, Sector and Symbol

Industry
Drug Delivery
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,000
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£565.60 million
Cash Flow
GBX 88.30 per share
Book Value
GBX 341.90 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.23 billion
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Shaun Edward Chilton (Age 54)
    CEO & Exec. Director
    Comp: $662k
  • Richard Paling
    Interim Chief Financial Officer & Group Financial Controller
  • Mr. Sam Herbert
    Chief Operating Officer
  • Rob Fox
    VP of Investor Relations & Corp. Devel.
  • Ms. Amanda Miller
    Gen. Counsel & Company Sec.
  • Mr. David Bryant
    Director of Corp. Devel.
  • Jessica Archer
    Global HR Director
  • Mr. Mark Corbett
    Managing Director of Global Access Division
  • Mr. Johannes Willemse (Age 54)
    Chief Commercial Officer
  • Mr. Ivo Timmermans M.D. (Age 62)
    MBA, Chief Medial Officer













CLIN Stock - Frequently Asked Questions

How have CLIN shares performed in 2023?

Clinigen Group's stock was trading at GBX 925 at the start of the year. Since then, CLIN stock has increased by 0.0% and is now trading at GBX 925.
View the best growth stocks for 2023 here
.

How were Clinigen Group's earnings last quarter?

Clinigen Group plc (LON:CLIN) announced its quarterly earnings data on Thursday, September, 17th. The company reported $65.60 earnings per share for the quarter, topping the consensus estimate of $63.50 by $2.10.

Is Clinigen Group a good dividend stock?

Clinigen Group (LON:CLIN) pays an annual dividend of GBX 0.08 per share and currently has a dividend yield of 0.82%. The dividend payout ratio is 0.53%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for CLIN.

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Applications (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), RTI International Metals (RTI), General Electric (GE) and NetApp (NTAP).

What is Clinigen Group's stock symbol?

Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How do I buy shares of Clinigen Group?

Shares of CLIN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Clinigen Group's stock price today?

One share of CLIN stock can currently be purchased for approximately GBX 925.

How much money does Clinigen Group make?

Clinigen Group (LON:CLIN) has a market capitalization of £1.23 billion and generates £565.60 million in revenue each year.

How many employees does Clinigen Group have?

The company employs 1,000 workers across the globe.

How can I contact Clinigen Group?

Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The official website for the company is www.clinigengroup.com. The company can be reached via phone at +44-1283-495010.

This page (LON:CLIN) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -